dexamethasone, Hepion

Remember President Trump Taking Dexamethasone? Hepion’s (HEPA) CRV431 demonstrated reduced lung inflammation and damage...

Hepion (HEPA) Announces FDA Clearance of IND Application for CRV431 for COVID-19
PetVivo, Biotech Stock Review

And Slowly But Surely..We Have Another 10-Bagger. PetVivo (PETV).

Things moving rather swimmingly at Pet-Vivo (PETV). Well, chart-wise. REWARDS GO TO THE PATIENT?
Hapbee

Jim Kwik and Kevin Harrington Join Hapbee Technologies (HAPB) Board.

Hapbee Announces Additions to Advisory Board December 17, 2020 New Advisors Bring Decades of Entrepreneurial ExperienceWellness...
HAPBEE

Hapbee (HAPB): The Netflix of Feelings

After 15 years, $70 million spent on R&D, and 350,000+ hours of testing, this "Netflix of Feelings" wearable technology is finally...
Aphex

Aphex BioCleanse Systems (SNST) Signs European Supply and Private Label Agreement for DermAphex® and...

PITTSFORD, N.Y. , Dec. 16, 2020 /PRNewswire/ -- Aphex BioCleanse Systems, Inc. (OTCPK: SNST) ("Aphex" or "the Company") , a sanitization solutions company focused on the development and distribution...
BioSig, Biotech Stock Review

BioSig (BSGM) Achieves First Commercial Sale of Three PURE EP Systems

Sale Marks Milestone for Company's Commercial expansion at leading Center of Excellence Westport,...
Cyclophilin, Biotech Stock Review

Adding Hepion Pharma (HEPA) $1.73 to Watch List.

Adding Hepion Pharma ($1.73) to Watch List. Oh My. What Did We Find Here? Oh my…and Oh boy....
Internet Stock Review

Newsletter: Institutional Analyst. And Yes, We Have Another Double.

1. Dalrada (DFCO) $0.19. And Yes, We Have Another Double!2. Dyadic (DYAI) $6.40. We're Up 392%, Video Presentation.3....

Dalrada (DFCO) Appoints Gregory L. Remsen To Vice President of Strategic Relationships.

Dalrada Financial Corporation Appoints Gregory L. Remsen To Vice President of Strategic Relationships DALRADA NEWS ARCHIVE

Committed to Win. C-1 and Dyadic’s (DYAI) Drive to Make Vaccines Affordable Worldwide.

Dyadic International, Inc. (NASDAQ: DYAI) – We are a global biotechnology company focused on further improving and leveraging the patented and proprietary...

Latest article

Nine Page Summary Report on GeoVax (GOVX)

This is a great long-term story. We’re telling you. (March 2024) When we finished writing our earlier...

GeoVax (GOVX) Provides First Half 2024 Business Update.

Award of BARDA Project NextGen contract represents a significant milestone event; Total value...